^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) + Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case report
Published date:
03/27/2023
Excerpt:
A 64-year-old male was diagnosed with advanced intrahepatic cholangiocarcinoma with ERBB2 (HER2) 3 + amplification determined by tissue-based testing and confirmed by next-generation sequencing. The patient was treated with pyrotinib added to pembrolizumab and lenvatinib... PET-CT after 6 months of treatment showed a partial response. The progression-free survival with second-line treatment was 17 months.
DOI:
https://doi.org/10.1186/s12957-023-02983-1
